Clinical Trials

Clinical Trial Detail

Return to search results.

FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer

Complete title: Quantitative Dynamic PET and MRI and Breast Cancer Therapy

Research Study Number       7587
    
Principal Investigator       Jennifer Specht, MD
    
Phase       NA

Look up trial at NIH

Research Study Description

This clinical trial studies fludeoxyglucose F 18 (FDG) positron emission tomography (PET) and dynamic contrast-enhanced (DCE)-magnetic resonance imaging (MRI) in predicting response to treatment in patients with breast cancer. Comparing results of diagnostic procedures done before, during, and after chemotherapy may help doctors predict a patient's response to treatment and help plan the best treatment.

Eligibility Criteria (must meet the following to participate in this study)

Ages Eligible for Study: 18 Years and older

Genders Eligible for Study: Both

- Pathologically confirmed breast cancer, determined to be a candidate for primary systemic (neoadjuvant) therapy and for surgical resection of residual primary tumor following completion of neoadjuvant therapy

- Primary tumor 2.0 cm or greater, and/or clinical evidence of axillary disease (palpable N1 or N2 or biopsy proven)

- No obvious contraindications for primary chemotherapy

- Able to lie still for PET and MRI scanning

- Able to understand and willing to sign a written informed consent document and a Health Insurance Portability and Accountability Act (HIPAA) authorization in accordance with institutional guidelines

Other eligibility criteria may apply.

Exclusions (conditions that would prevent participation in this study)

- Serious systemic illness other than breast cancer

- Contraindication to MRI or history of adverse reaction to gadolinium

- Evidence of distant disease outside of regional lymph nodes

- Pregnant

- Poorly controlled diabetes mellitus (fasting blood glucose > 200)

- Prior systemic cancer therapy

Other exclusion criteria may apply.



Research Study Number       7587
    
Contact       Seattle Cancer Care Alliance Intake Office
    
Telephone       800-804-8824 / 206-288-1024
    
   

Keywords
Breast Cancer; Solid Tumors

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials

Fred Hutchinson Cancer Research Center is a world leader in research to prevent, detect and treat cancer and other life-threatening diseases.